ARAY: Accuray Inc Market Cap to Revenue
The development of exclusive CyberKnife robots allows Accuray Incorporated (ARAY) to implement premium pricing. On GURU.Markets, the company's rolling P/S captures the impact of this strategy, where 0.00 shapes the current metric. A stable brand image within the oncology community and low sensitivity to macroeconomic shocks, driven by long-term government equipment procurement, ensure the resilience of the asset's quotes.
Analytical breakdowns for Accuray Inc. (ARAY)
- stock value and consensus price forecast:
- market capitalization information:
- book value of equity indicators:
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Accuray Incorporated|ARAY - Long-Term Debt to Capital|Short-Term Debt to Capital Accuray, Inc.|ARAY - Company Total Debt|Debts to Book Value Accuray Inc.|ARAY - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Accuray Incorporated|Interim Coverage Ratio accuray.com
- business earnings and investment ratios data:
ARAY - Company Net Income|Net Profit Forecast Accuray Incorporated|ARAY - P/E Multiple|Projected Price to Earnings Accuray Inc|ARAY - Price/Earnings to Growth Ratio|Company Value to EBITDA Accuray Inc.|ARAY - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Accuray Incorporated|ARAY - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months accuray.com|ARAY - Earnings per share growth in current year|Expected net earnings per share growth next year Accuray Incorporated
- sales revenue and business income indicators:
Summary company analytics:ARAY - accuray.com
The P/S multiple determines the market value of Accuray Incorporated relative to its annual sales volume, measuring the premium investors are willing to pay per unit of revenue. By analyzing the price-to-sales ratio, one can assess the fairness of the capitalization of this high-tech business, where the value of CyberKnife systems and the precision of radiosurgery should be reflected in the company's valuation dynamics relative to industry standards.
Who Accuray Incorporated competes with
P/S Multiple beigene.com (ONC)|P/S Multiple HALO (Halozyme)|RVMD - Market Cap to Revenue|Ascentage - P/S Multiple|CG Oncology Therapeutics (CGON) - Market Cap to Revenue|URGN (UroGen Pharma Ltd.) - Market Cap to Revenue|bicara.com (BCAX) - P/S Multiple|Price-to-Revenue Ratio Personalis|ERAS: Market Capitalization-to-Revenue Ratio|P/S Multiple DCTH|P/S Multiple Y-mAbs Corp (YMAB)|Aura Biosciences, Inc. - Market Cap to Revenue|Candel Therapeutics Inc. (CADL) - Price to Sales|SLS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ACTU (Actuate Therapeutics Inc.)|CTOR: P/S Multiple|HURA - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Protara Therapeutics|Market Cap to Revenue Ratio FATE (fatetherapeutics.com)|P/S Multiple WHWK|Market Cap to Revenue tscan.com TCRX|Price-to-Revenue Ratio Champions Oncology, Inc. CSBR|XBiotech Inc (XBIT) - Price to Sales|CVM - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio OSTX (ostherapies.com)|Radiopharm Theranostics (RADX) - Price-to-Revenue Ratio|Price-to-Sales Ratio ARTV (Artiva Biotherapeutics)|Price-to-Revenue Ratio Adlai Nortye Ltd|Price to Sales Veru Corporation VERU|Price-to-Revenue Ratio Tempest Therapeutics (TPST)|XLO (xiliotx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RENB (Renovaro)|P/S Multiple Mural Oncology PLC MURA|KAPA: Market Cap to Revenue|OnKure Therapeutics Inc - Market Cap to Sales Volume|GDTC: P/S Multiple|Price to Sales Curis (CRIS)|APLM (Apollomics Inc.) - P/S Multiple|Market Cap to Revenue Ratio THAR (Tharimmune Inc)|P/S Multiple ADVB|P/S Multiple Genprex Inc (GNPX)|Price-to-Revenue Ratio Calidi Biotherapeutics, Inc. CLDI|Market Capitalization-to-Revenue Ratio SBFM|Xenetic Bio - P/S Multiple|SLRX - P/S Multiple|PPBT (Purple Biotech Corp) - Market Cap to Revenue|Price to Sales American Oncology Network, Inc. (AONC)|BGNE (BeiGene, Ltd.) - P/S Multiple|Market Cap to Revenue checkpointtx.com (CKPT)|P/S Multiple ELEV|P/S Multiple icadmed.com (ICAD)|Price-to-Revenue Ratio Ikena Oncology IKNA|NTBL: Market Cap to Revenue Ratio|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Price to Sales Ascentage Pharma Group International (AAPGV)
